

Tchaikapharma High Quality Medicines Inc.
Interim statement of Financial status
as of 30 of June 2021

	30.06.2021	31.12.2020
	<i>BGN'000</i>	<i>BGN'000</i>
ASSETS		
Non-current assets		
Property, plant and equipment	36 643	37 123
Intangible assets	3 376	3 816
Assets with usable assets	105	210
Trade receivables	5 176	5 176
Total non-current assets	45 300	46 325
Current assets		
Inventories	10 736	10 842
Trade and other receivables	61 920	60 084
Current corporate income tax	14	14
Treasury shares redeemed	-	1
Cash and cash equivalents	27	45
Total current assets	72 697	70 986
Total assets	117 997	117 311
LIABILITIES		
Equity		
Share capital	82 200	82 200
Reserves	12 094	12 032
Retained earnings	5 558	2 904
Total	99 852	97 136
Non-current liabilities		
Long-term loans	1 946	1 731
Deferred tax liabilities	1 139	1 139
Retirement benefit obligations	194	194
Total non-current liabilities	3 460	3 064
Current liabilities		
Trade and other liabilities	4 461	6 583
Short-term loans	9 782	9 783
Current portion of long-term loans	479	541
Current corporate income tax		
Other tax liabilities	144	204
Total current liabilities	14 866	17 111
Total liabilities	18 145	20 175
Total equity and liabilities	117 997	117 311

Date of preparation: 29.07.2021


Sofia

Prepared by:.....

/ P. Moneva /

Executive Director:.....

/B. Georgiev/



Tchaikapharma High Quality Medicines Inc.
Interim statement of comprehensive income
as of 30 of June 2021

	30.06.2021	30.06.2020
	<i>BGN'000</i>	<i>BGN'000</i>
Revenue	22 302	21 579
Other income	21	54
Total income	22 323	21 633
Carrying amount of goods sold	(462)	(554)
Changes in inventories of finished products and work in progress	613	(541)
Materials and services	(14 467)	(13 123)
Personnel expenses	(2 691)	(2 247)
Depreciation / amortisation expenses	(2 037)	(1 910)
Other expenses	(282)	(85)
Finance income	11	32
Finance costs	(196)	(189)
Total expenses	(19 511)	(18 617)
Profit before taxation	2 812	3 016
Corporate income tax expense	(96)	(90)
Profit/Loss for the period	2 716	2 926
Total comprehensive income for the period	2 716	2 926
Earnings per share / in BGN per 1 share /	0.03	0.04

Date of preparation: 29.07.2021

Sofia

Prepared by:.....

/ P. Moneva /

Executive Director:.....

/B. Georgiev/



Tchaikapharma High Quality Medicines Inc.
Interim cash flow statement
as of 30 of June 2021

	30.06.2021	30.06.2020
	<i>BGN'000</i>	<i>BGN'000</i>
Cash flows from operating activities		
Proceeds from sale of finished products, goods and services	16 464	17 947
Payments to suppliers of materials, goods and services	(11 089)	(11 407)
Payments to personnel	(2 478)	(2 101)
Payments of interest and dividends	(96)	(232)
Other proceeds / payments	(1 774)	(2 378)
<i>Net cash flows</i>	1 027	1 829
Cash flows from investing activities		
Payments on non-current assets acquired	(731)	(1 234)
<i>Net cash flows</i>	(731)	(1 234)
Cash flows from financial activities		
Proceeds from loans	82	82
Payments on loans	(185)	(180)
Payment of interest, dividends	(14)	(19)
Payments on finance lease	(197)	(172)
<i>Net cash flows</i>	(314)	(289)
Change in cash and cash equivalents	(18)	306
Cash and cash equivalents at the beginning of the period	45	40
Cash and cash equivalents at the end of the period	27	346

Date of preparation: 29.07.2021

Sofia

Prepared by:.....

/ P. Moneva /

Executive
Director:.....

/B. Georgiev /



Tchaikapharma High Quality Medicines Inc.
Interim statement on changes in equity
as of 30 of June 2021

	Registered (share) capital <i>BGN'000</i>	Revaluation reserves <i>BGN'000</i>	Other reserves <i>BGN'000</i>	Retained earnings / loss <i>BGN'000</i>	Total equity <i>BGN'000</i>
Balance as of 01.01.2020	82 200	4 099	7 676	2 568	96 543
Profit/loss for the period				604	604
Other comprehensive income		(11)			(11)
Including from tax effect of the revaluation of property, plant and equipment					
Total comprehensive income		(11)		604	593
Issue of shares by the owners					
Dividends accrued					
Tantiemmes accrued					
Profit transferred to reserves			268	(268)	
Total amount of income and expenses recognised during the period			268	(268)	
Balance as of 31.12.2020	82 200	4 088	7 944	2 904	97 136
Balance as of 01.01.2021	82 200	4 088	7 944	2 904	97 136
Profit/loss for the period				2 716	2 716
Other comprehensive income					
Total comprehensive income				2 716	2 716
Issue of shares by the owners					
Dividends accrued					
Tantiemmes accrued					
Profit transferred to reserves			62	(62)	
Total amount of income and expenses recognised during the period					
Balance as of 30.06.2021	82 200	4 088	8 006	5 558	99 852

Date of preparation: 29.07.2021
Sofia

Prepared by:.....

/P. Moneva/

Executive Director:.....

/B. Georgiev /

